Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Anthem

Elanco Animal Health Inc

Zoetis

The Vanguard Health Care Fund (Trades, Portfolio) recently disclosed its first quarter 2022 portfolio, revealing that its top five trades for the quarter included a new position in Zoetis Inc. ( ZTS , Financial), a boost to its holding in Daiichi Sankyo Co. Ltd. ( TSE:4568 , Financial), the closure of its position in Elanco Animal Health Inc. ( ELAN , Financial) and reductions to its holdings in Bristol-Myers Squibb Co. ( BMY , Financial) and Anthem Inc. ( ANTM , Financial).

Vanguard Health Care Fund's Top 5 Trades in the 1st Quarter

Unlike out-of-date bread, pharma companies don't usually throw out products that have become stale because many of them have long-term market relevance and will continue to be in demand for decades to come. However, a high percentage of any pharma company's drugs getting musty might indicate where the company and its stock are headed, since a lack of fresh revenue sources means growth could be limited or nonexistant going forward.

Bristol-Myers Has the Stalest Product Line, Says Evaluate

McKesson

Vertex Pharmaceuticals

They perhaps, not so coincidentally, are all in the pharmaceutical business.

3 Safe Stocks to Buy That Are Crushing the Market

The EC has approved its cancer drug Opdivo, together with chemotherapy, to treat esophageal cancer.

Bristol-Myers Squibb Snags Another Approval for This Mega-Blockbuster Drug

Alcoa

AbbVie

Bunge Global SA

Chevron

DuPont de Nemours

Hess

Host Hotels & Resorts

Leidos Hld

Most mutual funds have losses this year amid the market's sell-off. But JPMorgan Large Cap Value Fund is in positive territory.

Stocks That Lift This JPMorgan Fund In Down Market

CVS Health

GlaxoSmithKline

Moderna

Pfizer

Should investors' be looking at these health care stocks this earnings season?

5 Health Care Stocks For Your May 2022 Watchlist

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in Bank of America Securities 2022 Healthcare Conference

Bristol Myers Squibb to Participate in Bank of America Securities 2022 Healthcare Conference

Biogen

Eli Lilly

Merck

Reporters and analysts covering first-quarter earnings from drug companies may have noticed a change in how they account for upfront payments made to finance research and development at companies in which they have acquired equity stakes.

Called to Account: Drug companies are making an accounting change after the SEC cracked down on Biogen

British American Tobacco

Omega Healthcare Investors

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

The data suggests that a recession has begun or will begin shortly. I am repositioning my portfolio to endure the next recession.

Recession Is Here. I'm Buying These 4 Dividend Stocks To Prepare

Bristol-Myers (BMY) earnings beat estimates in the first quarter of 2022. Sales jump year over year on the back of Eliquis and new products.

Bristol-Myers (BMY) Q1 Earnings Beat Estimates, Guidance Down

Bristol-Myers Squibb Company (NYSE:BMY ) Q1 2022 Results Conference Call April 29, 2022 8:00 AM ET Company Participants Tim Power - VP & Head, IR Giovanni Caforio - Board Chair & CEO David Elkins - CFO Chris Boerner - Chief Commercialization Officer Samit Hirawat - Chief Medical Officer and Head of Global Drug Development Conference Call Participants Chris Schott - JPMorgan Chris Shibutani - Goldman Sachs Geoff Meacham - Bank of America Seamus Fernandez - Guggenheim Evan Seigerman - BMO Andrew Baum - Citi Steve Scala - Cowen Luisa Hector - Berenberg Terence Flynn - Morgan Stanley Dane Leone - Raymond James Operator Good day, and welcome to the Bristol-Myers Squibb 2022 First Quarter Results Conference Call. Today's conference is being recorded.

Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Q1 2022 Results - Earnings Call Transcript

Colgate-Palmolive

Exxon Mobil

Core PCE Inflation at a 40-Year High in March.

Core PCE Inflation at a 40-Year High in March

Inflation was clear and present in March, but a large chunk of it was due to food and energy prices.

PCE +6.6%, Another 40-Year High; XOM, CL, BMY Report

Bristol Myers (BMY) delivered earnings and revenue surprises of 2.08% and 3.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers Squibb (BMY) Q1 Earnings and Revenues Surpass Estimates

Bristol-Myers Squibb Co (NYSE: BMY) has posted Q1 revenues of $11.65 billion, an increase of 5% Y/Y (7% constant currency), beating the consensus of $11.36 billion.  Eliquis, Opdivo, cell therapy products, and Reblozyl drove sales growth.

Bristol Myers Q1 Earnings Surpass Street Expectations, Lowers FY22 Guidance

Drugmaker Bristol Myers Squibb posted slightly better-than-expected first-quarter earnings on Friday on growth of sales of its blood thinner Eliquis and cancer drug Opdivo, but said it no longer expects sales growth in 2022 due to stiff generic competition overseas for blood cancer drug Revlimid.

Bristol Myers 1st-quarter sales up on Eliquis, Opdivo

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2022, which reflect robust in-line product growth, increased adoption of new product portfolio and strong commercial execution. “We continue to execute against our strategic priorities, deliver solid revenue and earnings growth and advance our product pipeline,” said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. “Thanks to our team's hard work and de

Bristol Myers Squibb Reports First Quarter Financial Results for 2022

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. Food and Drug Administration Approves Camzyos (mavacamten)

U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms

AstraZeneca

Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.

Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN

Bristol-Myers (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Bristol-Myers (BMY) Might Surprise This Earnings Season

BMY stock has seen a 23% rise YTD, outperforming its peers and the broader markets, primarily due to an increase in dividends and boosting its share repurchase program.

What To Expect From Bristol Myers Squibb Stock After Q1 Results?

Bristol-Myers (BMY) Q1 earnings might have gained from strong demand for Eliquis and incremental contribution from newer drugs. Operating expenses might have jumped on broader portfolio-related costs.

Bristol-Myers (BMY) to Post Q1 Earnings: Is a Beat in Store?

Between the time markets closed on Tuesday and before they opened again on Wednesday, more than 600 U.S.

Earnings Previews: AbbVie, AstraZeneca, Bristol-Meyers Squibb

Nektar Therapeutics

Nektar Therapeutics (NASDAQ: NKTR) announced a new strategic plan to prioritize key research and development efforts and cut 70% of its workforce, including several changes to its executive team.  Dimitry Nuyten, Nektar's Chief Medical Officer, will step down from his.

After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring

Kroger

Occidental Petroleum

They aren't the most exciting stocks out there, but these long-term winners have what they need to keep climbing.

News for Bristol-Myers Stock (BMY)